People's Republic of China


My-BioMed Biotechnology (MBM) was founded in 2016. MBM business covers precision medicine; artificial intelligence and digital pathology, cancer early detection, diagnostic and prognostic biomarkers, as well as in other diseases. MBM is committed to bridging world innovations in precision medicine. It is a precision medicine platform in China aimed at the transformation and commercialization of diagnostics and medical artificial intelligence technologies. MBM introduces technologies and products that are clinically proven, with a focus on oncology and cardiovascular.

Visit the MBMbio website

Subscribe for updates

A weekly update of what’s on the Global Agenda

© 2021 World Economic Forum

Privacy Policy & Terms of Service